FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals
ConclusionsIn this study, we found that a substantial portion of peripartum women moved within the country around the time of delivery and experienced a significantly higher risk of mortality. Despite the scale-up of universal ART and declining trends in maternal mortality, there is an urgent need to derive a greater understanding of the mechanisms underlying this finding and to develop targeted interventions for mobile HIV-positive peripartum women.
Conclusion: Availability and accessibility of PMTCT programme services are still problematic. The study has the potential to inform development of strategies that may facilitate access to care for PMTCT programme clients. PMID: 32200723 [PubMed - in process]
Authors: Mathad JS, LaCourse SM, Gupta A PMID: 32202066 [PubMed - in process]
CONCLUSIONS: Experiences from the PROMISE study illustrate the challenges of enrolling in longer term studies in the setting of rapidly evolving prevention and treatment standards priorities. The lessons learned will help the community, site investigators, and study coordinators in the design and implementation of future clinical trials. PMID: 32191142 [PubMed - as supplied by publisher]
Objective: To investigate factors contributing to preterm birth (PTB), including cART use and clinical and social determinants of health, in women living with HIV (WLWH) from British Columbia, Canada. Design: Retrospective observational cohort. Methods: We investigated the effect of cART use and other clinical and demographic factors on spontaneous PTB (sPTB) rates (
Objectives: Measuring retention is critical for antiretroviral therapy (ART) management and program monitoring; however, many definitions and data sources, usually from single health facilities, are used. We used routine electronic data, linked across facilities, to examine the impact of definitions and data sources on retention estimates among women in Cape Town, South Africa. Design: Retrospective cohort study. Methods: We compiled routine electronic laboratory, pharmacy and clinic visit data for 617 women who started ART during pregnancy (2013–2014) and estimated 24-month retention using different definiti...
Conclusion: Substantial HIV incidence among pregnant and breast-feeding women in SSA, even in the current era of combination HIV prevention and treatment, underscores the need for prevention tailored to high-risk pregnant and breast-feeding women.
Authors: Kalinjuma AV, Glass TR, Weisser M, Myeya SJ, Kasuga B, Kisung'a Y, Sikalengo G, Katende A, Battegay M, Vanobberghen F, KIULARCO Study Group Abstract INTRODUCTION: Lifelong antiretroviral therapy (ART) improves health outcomes for HIV-positive individuals, but is jeopardized by irregular clinic attendance and hence poor adherence. Loss to follow-up (LTFU) is typically defined retrospectively but this may lead to biased inferences. We assessed incidence of and factors associated with LTFU, prospectively and accounting for recurrent LTFU episodes, in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) o...